Cassava Sciences Inc

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cassava Sciences advances Phase III trial with strong financial footing

Cassava Sciences is progressing well with Phase III trial milestones and financial stability, poised to announce critical trial results by year-end.
While facing challenges in data accuracy and increased expenses, the company's proactive approach and strategic planning present significant growth opportunities.
By focusing on innovation and market transformation, Cassava Sciences is positioned to redefine Alzheimer's disease diagnosis and treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

The stock price of Cassava Sciences Inc (NASDAQ: SAVA) increased by over 17% during intraday trading. This is why it happened.

SAVA Stock Price Increases Over 17% Intraday: Why It Happened

Cassava Sciences stock has been hammered for no good reason and is likely to rebound. AVA stock is still worth over $900 especially given the recent positive 9-month results of its Alzheimer's drug Simufilam.

Cassava Sciences Stock Has Been Hammered For No Good Reason and Is Likely To Rebound

- Conference Call Today at 9 a.m. ET - - Conference Call Today at 9 a.m. ET -

Cassava Sciences Reports Second Quarter 2021 Financial Results

AMC Entertainment

Robinhood

Nikola

These stocks look to be more trouble than they're worth.

5 Ultra-Popular Stocks to Avoid Like the Plague in August

- Call-in on Tuesday, August 3rd at 9 a.m. ET - - Call-in on Tuesday, August 3rd at 9 a.m. ET -

Cassava Sciences Announces Conference Call for Second Quarter Financial Results

Simufilam is the first AD drug to show a cognitive improvement at 9 months, with a gaudy 18% mean improvement from baseline. Simufilam also showed a growing behavioral benefit.

Cassava Sciences' Simufilam Is The First Alzheimer's Drug To Work At 9 Months, And The Benefit Is Growing

The stock price of Cassava Sciences Inc (NASDAQ: SAVA) fell by over 25% during intraday trading. These are some details you should know.

SAVA Stock Fell 23.61%: Details You Should Know

As Cassava Sciences made progress in treating Alzheimer's, SAVA stock is on a powerful path to significantly higher prices. The post Cassava Sciences Stock Has Plenty of Momentum After Positive Clinical Data appeared first on InvestorPlace.

Cassava Sciences Stock Has Plenty of Momentum After Positive Clinical Data

Annovis Bio

Anavex Life Sciences

A clinical-trial flop for Annovis Bio is reminding investors that developing new drugs for Alzheimer's disease is an extremely risky business.

Here's Why Annovis Bio, Anavex Life Sciences, and Cassava Sciences Sank on Thursday

AUSTIN, Texas, July 29, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced positive biomarker data from an open-label study of simufilam, the Company's investigational drug for the treatment of Alzheimer's disease.

Cassava Sciences Announces Positive Biomarker Data with Simufilam in Alzheimer's Disease

AUSTIN, Texas, July 29, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) announced positive clinical data today from an interim analysis of an open-label study with simufilam, the Company's investigational drug for the treatment of Alzheimer's disease.

Cassava Sciences Announces Positive Cognition Data With Simufilam in Alzheimer's Disease

Biogen

This popular life science company has a fair but risky shot of developing a novel drug to treat Alzheimer's disease.

Should You Invest in This Seemingly Unstoppable Alzheimer's Biotech?

Cassava Sciences shares are +3,300% in the past year, but the upside could continue until the $4.5bn market cap biotech achieves a >$50bn valuation.

Cassava Sciences: Critical Alzheimer's Data Due Thursday Offers Upside Potential

5 Reasons Cassava Sciences Could Still Be The Most Undervalued Stock In The Market

Cassava Sciences Inc. (NASDAQ: SAVA) shares were moving Monday after the company announced positive clinical data with SavaDx. SavaDx is an investigational diagnostic to detect Alzheimer's disease with a simple blood test.

Cassava Sciences Stock Looks Ready To Break Out If This Pattern Is Confirmed

AUSTIN, Texas, July 26, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced positive clinical data with SavaDx, an investigational diagnostic/biomarker to detect Alzheimer's disease with a simple blood test. SavaDx was used to measure plasma levels of altered filamin A before and after simufilam treatment in patients with Alzheimer's disease. In this Phase 2b randomized, controlled trial sponsored by the National Institutes of Health (NIH), simufilam significantly reduced plasma levels of altered filamin A in Alzheimer's patients treated for 28 days. Plasma levels of p-tau181 also dropped significantly in these same patients.

Cassava Sciences Announces Positive Data with SavaDx from a Randomized Controlled Phase 2b Study of Simufilam

Cassava Sciences stock could jump with its upcoming Alzheimer's results. SAVA stock options show the lofty expectations investors have.

Cassava Sciences Stock Could Be Worth $900 After Its Upcoming Alzheimer's Results

India Globalization Capital

Screen capture via IGC's healthcare subsidiary Hyalolex. "Drops of Clarity" is their just-patented Alzheimer's treatment.

An Unforgettable Week For Alzheimer's Treatment Stocks: Two Of Our Recent Top Names Spike On News Of Potentially Promising Treatments

ProShares Ultra Bloomberg Natural Gas

Peabody Energy

Cleveland-Cliffs

Generac Holdings

Green Plains

Overstock.com

Japanese gameshow contestant versus bear. Image via TMZ.

Update On A Bear-Proof Portfolio: The Portfolio We Presented Earlier This Week Is Off To A Fast Start

On Thursday, Cassava Sciences, Inc (NASDAQ: SAVA) smashed through a resistance level at $117.54, made 21 years ago between its initial public offering date of June 14, 2000 and December of that year. On Wednesday, the biopharmaceutical company announced it will present new clinical-trial data from a Phase 2 trial of its drug simufilam at the Alzheimer's Association International Conference (AAIC) on July 29.

Cassava Sciences Stock Soars In Anticipation Of Alzheimer's Data: A Technical Analysis

Risk-averse investors may want to look elsewhere.

2 High-Risk, High-Reward Stocks That Could Go to the Moon

Meme stock Cassava Sciences Inc. (NASDAQ:SAVA) shares surged more than 27% on Wednesday after revealing plans to present data on its Alzheimer's drug, Simufilam, on 29th July. Cassava will read out its interim analysis on a 9-month treatment with Simulflam at the 2021 Alzheimer's Association International Conference (AAIC) in Denver.

Cassava Sciences stock price forecast for Q3 after shares rally 27%

Investors are excited about upcoming presentations scheduled for the annual Alzheimer's Association International Conference.

Here's Why Cassava Sciences Is Surging Today

SAVA stock is flying upward today as investors clamor to hear information around two new products. Investors should save two upcoming dates.

SAVA Stock: Two Dates Cassava Investors Need to Mark on Their Calendars

The stock price of Cassava Sciences Inc (Nasdaq: SAVA) increased by over 33% during intraday trading. This is why it happened.

News for Cassava Sciences Inc Stock (SAVA)